SCHEMBL4179371

SCHEMBL4179371

N#C/C(=C\c1cccc(O)c1)S(=O)(=O)Cc1ccccc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 6/20 0.51
▸ ALDH1A1 P00352 6/20 0.46
▸ SMN1; SMN2 Q16637 3/20 0.46
▸ MEN1 O00255 3/20 0.46
▸ KMT2A Q03164 3/20 0.46
▸ HPGD P15428 3/20 0.46
▸ PKM P14618 2/20 0.46
▸ L3MBTL1 Q9Y468 2/20 0.46
▸ POLB P06746 1/20 0.46
▸ GAA P10253 1/20 0.46
▸ ALPG P10696 1/20 0.46
▸ ALOX15 P16050 1/20 0.46
▸ ALOX12 P18054 1/20 0.46
▸ HSD17B10 Q99714 1/20 0.46
▸ TDP1 Q9NUW8 1/20 0.46
▸ EGFR P00533 1/20 0.43
▸ MMP1 P03956 2/20 0.40
▸ MMP2 P08253 2/20 0.40
▸ MMP9 P14780 2/20 0.40
▸ MAPT P10636 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4179378 1.00 KDM4E (0.51) KDM4EALDH1A1SMN1; SMN2MEN1KMT2A
SCHEMBL4179377 1.00 KDM4E (0.51) KDM4EALDH1A1SMN1; SMN2MEN1KMT2A
SCHEMBL4169979 0.88 KDM4E (0.44) KDM4EALDH1A1SMN1; SMN2MEN1KMT2A
SCHEMBL4169977 0.88 KDM4E (0.44) KDM4EALDH1A1SMN1; SMN2MEN1KMT2A
SCHEMBL4169974 0.88 KDM4E (0.44) KDM4EALDH1A1SMN1; SMN2MEN1KMT2A
SCHEMBL4182741 0.80 ALDH1A1 (0.53) KDM4EALDH1A1SMN1; SMN2MEN1KMT2A
SCHEMBL4182739 0.80 ALDH1A1 (0.53) KDM4EALDH1A1SMN1; SMN2MEN1KMT2A
SCHEMBL4182744 0.80 ALDH1A1 (0.53) KDM4EALDH1A1SMN1; SMN2MEN1KMT2A
SCHEMBL4174167 0.80 PKM (0.49) KDM4EALDH1A1SMN1; SMN2MEN1KMT2A
SCHEMBL4174172 0.80 PKM (0.49) KDM4EALDH1A1SMN1; SMN2MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090191193-A1 Aryl Vinyl Sulfides, Sulfones, Sulfoxides and Sulfonamides, Derivatives Thereof and Therapeutic Uses Thereof TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 2009-07-30 — — US claimed
US-20090191193-A1 Aryl Vinyl Sulfides, Sulfones, Sulfoxides and Sulfonamides, Derivatives Thereof and Therapeutic Uses Thereof TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 2009-07-30 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090191193-A1 Aryl Vinyl Sulfides, Sulfones, Sulfoxides and Sulfonamides, Derivatives Thereof and Therapeutic Uses Thereof ARSA, STS, SULT2A1 KDM4E 1688/4885ALDH1A1 249/4885SMN1; SMN2 448/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback